Tracks medicine adherence and symptoms in people with inflammatory bowel disease
Studies a remote monitoring tool in adults taking vedolizumab for bowel disease.
Plain-language title generated from the registry record
Registry title: Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
Key facts
- Where
- Chapel Hill, Chevy Chase, Cincinnati, Nashville, New Orleans, and New York, United StatesSee the 6 sites
Where in United States
- University of North CarolinaChapel Hill, United StatesTaking people
- Capital Digestive CareChevy Chase, United StatesNot yet recruiting
- University of CincinnatiCincinnati, United StatesNot yet recruiting
- Vanderbilt UniversityNashville, United StatesNot yet recruiting
- Tulane UniversityNew Orleans, United StatesNot yet recruiting
- NYU Langone HealthNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mercy Medical Center
- Trial code
- NCT06750731
- Record updated
- 9 October 2026
- Original description
The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, and inflammatory bowel disease type undetermined) initiating therapy with vedolizumab (Entvyio). The main questions it aims to answer are:Read full original descriptionShow less
Real World Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention (MONITOR Study)
The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis, and inflammatory bowel disease type undetermined) initiating therapy with vedolizumab (Entvyio). The main questions it aims to answer are:
1. Assess and compare adherence to intravenous (IV) and subcutaneous vedolizumab maintenance therapy in patients with IBD using a novel remote monitoring system. 2. Assess symptom response to vedolizumab post induction (week 6-8) and during maintenance therapy (week 22) using a novel remote monitoring system. 3. Assess time to response to vedolizumab during induction (weeks 0-6) using a novel remote monitoring system.
Researchers will compare medication adherence between participants using IV and subcutaneous vedolizumab maintenance therapy to see if adherence is lower with self-administration.
Participants will be asked to register adherence to medication using the novel remote monitoring system each time they take a dose of vedolizumab and to respond to two questions about bowel symptoms weekly for the first 6 weeks after starting vedolizumab then monthly thereafter for 6 months. Additionally, participants will be asked to enter information regarding demographics and social determinants of health at baseline and other variables listed below at baseline and at weeks 2, 6, 14, and 22 post baseline unless otherwise denoted:
* MARS-5 * Healthcare utilization (22 weeks only) * Harvey Bradshaw Index (Crohn's disease only) * Simple clinical colitis activity index (Ulcerative colitis only) * PROMIS Global Health Scale * PROMIS Anxiety * PROMIS Depression * PROMIS Sleep Disturbance * PROMIS Pain Interference * PROMIS Physical Function * IBD Self-Efficacy * Attitudinal Survey (22 weeks only)
Inclusion: At least 18 years of age or older; Have documented IBD based on usual diagnostic criteria including clinical symptoms and findings from endoscopy, radiology studies, and histology; Initiating treatment with vedolizumab; Have access to a mobile smartphone (iPhone 7 or later; Android release date 2012 or later) with reliable data and/or Wi-Fi access; Ability to understand the protocol and provide informed consent in English or Spanish.
Exclusion: Imminent surgery (within the next 60 days); History of short bowel syndrome; Uncontrolled medical or psychiatric disease at the opinion of the investigator; Degenerative neurologic condition; Unstable angina; Symptomatic peripheral vascular disease; Malignancy within the last 2 years (excluding squamous or basal cell cancers of the skin); Poorly controlled depression, mania, and schizophrenia; Serious active infection requiring antimicrobial therapy (excluding CD patients with perianal CD on antibiotics); Inability to speak and read English or Spanish; Unable to comply with the study protocol including inability to access the internet and/or inadequate access to a smart device; Unable to access vedolizumab due to insurance restrictions; Unable to follow up at respective sites due to insurance restrictions or other barriers (i.e., distance from patient's home to study site); Presence of an ileostomy, colostomy, ileoanal pouch anastomosis, or ileorectal anastomosis.